RhumbLine Advisers
ANTX icon

RhumbLine Advisers’s AN2 Therapeutics ANTX Stock Holding History

RhumbLine Advisers’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$118K Buy
+24,342
New +$105K ﹤0.01% 3471
2024
Q3 		– Sell
-250
Closed -$537 – 4201
2024
Q2 		$537 Hold
250
– – ﹤0.01% 4286
2024
Q1 		$812 Hold
250
– – ﹤0.01% 4161
2023
Q4 		$5.12K Hold
250
– – ﹤0.01% 3982
2023
Q3 		$4.02K Sell
250
-1,427
-85% -$16.2K ﹤0.01% 4017
2023
Q2 		$14.3K Sell
1,677
-10,033
-86% -$72.1K ﹤0.01% 3863
2023
Q1 		$116K Buy
11,710
+1,628
+16% +$18.1K ﹤0.01% 2836
2022
Q4 		$96K Buy
+10,082
New +$135K ﹤0.01% 2909

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

RhumbLine Advisers's ANTX Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in AN2 Therapeutics (ANTX) in Q2 2026: 24,342 shares worth $118K. The stake represents ﹤0.01% of the portfolio and ranks #3471 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in ANTX as recently as Q2 2024.

RhumbLine Advisers first reported a position in ANTX in Q4 2022 and has held it in 8 quarters since. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • RhumbLine Advisers held 24,342 shares of AN2 Therapeutics worth $118K as of Q2 2026.
  • AN2 Therapeutics was a new RhumbLine Advisers position in Q2 2026.
  • AN2 Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3471 holding.
  • RhumbLine Advisers first reported a position in AN2 Therapeutics in Q4 2022 and has held it in 8 quarters since.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.